Events

Transforming Biopharmaceutical Research with AI at The HESI Annual Meeting 2020.

TUESDAY 9 JUNE | VIRTUAL EVENT

Abstract

The Health and Environmental Sciences Institute (HESI)’s mission is to develop science for a safer, more sustainable world. For HESI’s Annual Meeting 2020, our Executive board director, Jackie Hunter, will take to the virtual stage to demonstrate how AI can be used right at the beginning of the R&D process to improve target identification and validation as well as being used to identify key pathways in disease. Benevolent’s technology platform can be used to better predict the properties of molecules including their safety leading to fewer compounds needing to be physically made. There are still considerable challenges in applying the technology – primarily around access to data, especially negative data and these will be discussed.

 

Prof. Jackie Hunter, BenevolentAI

Professor Jackie Hunter held senior positions at global pharmaceutical organisations including GSK, Proximagen and OI Pharma Partners before joining BenevolentAI as an Executive Board Director in 2016. She brings vast academic and business experience in the biomedical and pharmaceutical sectors. For her services to the pharmaceutical industry, she was awarded a CBE in 2010, Birthday Honours and the 2010 Women of Achievement in Science, Engineering and Technology Award for Discovery, Innovation and Entrepreneurship. She gives the company the insight it needs to operate its unique business model – one which sees it not only researching, but also developing the blueprint for new drugs.

REGISTER >

More Posts

You Might Also Like

News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022